Supplements
Does Omega-3 Help with Depression?
Depression affects roughly 280 million people worldwide, yet many are unaware that EPA-dominant omega-3 supplementation has a clinically meaningful — if underappreciated — role in mood regulation. Multiple meta-analyses now show that fish oil at the right dose and fraction can significantly reduce depressive symptoms, especially alongside standard care. The catch: formulation, baseline status, and inflammatory load determine almost everything.
Does Omega-3 Help with Depression?
Yes, for most people with diagnosed depression or elevated depressive symptoms. High-EPA omega-3 formulas reduce depression scores significantly in multiple meta-analyses — but the effect is strongest in people with true deficiency, those already on antidepressants, and those whose depression has an inflammatory component. People with normal omega-3 status and no inflammation may see modest or no benefit.
---
What the Clinical Evidence Actually Shows
The omega-3 and depression literature is now substantial enough to draw real conclusions. A 2016 meta-analysis by Mocking et al. pooled 13 randomized controlled trials (n = 1,233) and found that omega-3 supplementation produced a significant antidepressant effect, with the benefit driven almost entirely by the EPA fraction rather than DHA (Mocking et al., Translational Psychiatry 2016; PMID: 26978738). The standardized mean difference was moderate — comparable in magnitude to some second-line antidepressant agents.
An earlier landmark meta-analysis by Sublette et al. specifically separated EPA-dominant and DHA-dominant formulas and found that preparations with at least 60% of total omega-3 as EPA were significantly more effective than DHA-dominant preparations (Sublette et al., Journal of Clinical Psychiatry 2011; PMID: 21939614). This EPA-threshold finding has since been replicated, and it is the reason clinicians who use omega-3 for depression typically specify EPA-dominant products at 1–2 g of EPA per day rather than generic fish oil.
A 2019 systematic review by Appleton et al. analyzed 26 RCTs and concluded that omega-3 supplements probably reduce depressive symptoms compared with placebo, though effect sizes varied considerably by baseline status and study design (Appleton et al., British Journal of Nutrition 2021; doi: 10.1017/S0007114520003244). Studies in populations with objectively low omega-3 index scores showed larger effects, reinforcing the deficiency hypothesis.
Importantly, a 2022 secondary analysis of the VITAL trial — the largest omega-3 RCT to date (n > 25,000) — found no significant reduction in depression incidence at the population level with 1 g/day of omega-3, though subgroup analyses suggested benefit in those with elevated inflammatory markers at baseline (Okereke et al., JAMA 2022; PMID: 35997480). This is the main caveat: broad population supplementation without stratification by deficiency or inflammation does not produce dramatic results.
One additional piece of the puzzle comes from a 2019 network meta-analysis by Liao et al. that ranked omega-3 formulations head-to-head against one another. Their analysis of 19 trials (n = 1,563) found that pure EPA supplementation produced the largest effect size (SMD −0.61; 95% CI −0.91 to −0.31) compared with both DHA-only and balanced EPA+DHA preparations, and that doses of EPA in the 1–2 g/day range performed similarly to higher doses — suggesting a ceiling effect that makes extreme dosing unnecessary and potentially counterproductive (Liao et al., Translational Psychiatry 2019; PMID: 31383846).
The honest summary: EPA-dominant omega-3 at ≥1 g EPA/day is a well-supported adjunct for clinical depression, particularly when inflammation is elevated or omega-3 intake is low. It is not a standalone cure and works best alongside standard care.
---
The Mechanism: Why EPA Specifically Affects Mood
Omega-3 fatty acids — EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) — are long-chain polyunsaturated fats that the body cannot synthesize in meaningful quantities. They must come from diet or supplementation. When EPA is low relative to arachidonic acid (AA), the pro-inflammatory arm of eicosanoid signaling dominates, driving elevated IL-6, TNF-α, and CRP — all biomarkers consistently elevated in major depressive disorder.
EPA counteracts this by competing with AA for cyclooxygenase and lipoxygenase enzymes, shifting the balance toward anti-inflammatory resolvins and protectins. This matters for depression because neuroinflammation disrupts serotonin synthesis, reduces BDNF (brain-derived neurotrophic factor), and dysregulates the HPA axis — three pathways central to depressive illness.
A lesser-discussed pathway involves EPA's role in phospholipid remodeling. The Lands cycle describes a continuous process of incorporating and removing fatty acids from cell membrane phospholipids, and EPA competes directly with AA at the sn-2 position. When dietary EPA is chronically low, AA dominance at this position amplifies microglial activation and primes the brain's immune surveillance system toward excessive inflammatory signaling — a state increasingly described in the depression neuroscience literature as the "inflammatory subtype" of MDD. Correcting this imbalance via supplementation appears to shift microglia toward a less reactive phenotype, which may explain why EPA's antidepressant signal is strongest in people with measurably elevated CRP or IL-6 at baseline.
DHA, by contrast, is structurally incorporated into neuronal membranes and supports membrane fluidity and receptor signaling, but it is not converted to EPA in significant amounts and does not have the same anti-inflammatory potency at typical supplementation doses. This mechanistic difference explains the EPA-specificity finding in the meta-analyses above.
For people considering omega-3 for anxiety as well as depression, the mechanistic overlap through HPA axis regulation is meaningful — see our deeper look at omega-3 and anxiety research for that angle.
---
Dosage Protocol: What a Clinical Omega-3 Depression Trial Looks Like
The dose and formulation details that appear across positive trials are fairly consistent:
| Parameter | Clinical Trial Range | Practical Target |
|---|---|---|
| Total omega-3 daily | 1–4 g/day | 2–3 g/day |
| EPA fraction | ≥60% of total omega-3 | ≥1 g EPA specifically |
| DHA | Present but secondary | 0.5–1 g DHA |
| Duration | 8–16 weeks minimum | 12 weeks to assess effect |
| Form | Ethyl ester or triglyceride | Triglyceride preferred for absorption |
| Timing | With fat-containing meal | Improves absorption by up to 50% |
Subclinical depression and milder mood disturbances may respond at the lower end (1 g EPA/day). For major depressive disorder, most positive trials used 1–2 g EPA or combined EPA+DHA at 2–4 g total daily. Doses above 3 g/day of combined EPA+DHA warrant physician oversight due to potential effects on platelet aggregation.
Trials typically run 8–12 weeks before endpoints are assessed. If you are tracking biomarkers, the omega-3 index (% EPA+DHA in red blood cell membranes) is the most clinically meaningful marker — a target above 8% is associated with optimal cardiovascular and neurological outcomes.
For a broader look at what omega-3 fish oil accomplishes beyond mood, this evidence review of omega-3 benefits covers cardiovascular, inflammatory, and cognitive endpoints in detail.
One practical note on formulation: ethyl ester forms are the most common in clinical trials but have roughly 70% of the bioavailability of re-esterified triglyceride (rTG) forms when taken without a meal. If you are using an ethyl ester product, always take it with a high-fat meal; if budget allows, rTG forms deliver more EPA per gram absorbed and remove that variable from the equation entirely.
---
Who Benefits Most — and Who Probably Won't
Not everyone responding to an omega-3 supplement will notice a mood change. The following factors predict who is most likely to respond:
Higher responders:
- People with objectively low omega-3 index (<4%) or low dietary fish intake
- Those with elevated inflammatory markers (CRP >1 mg/L, high IL-6)
- People already taking an antidepressant (omega-3 appears to enhance SSRI response, possibly through membrane-mediated serotonin transporter modulation)
- Postpartum depression — DHA depletion during pregnancy is documented and severe (for the specific postpartum data, omega-3 and postpartum recovery covers this clinical niche)
- People with comorbid cardiovascular risk or metabolic syndrome
Lower or non-responders:
- Those with high dietary omega-3 intake already (fatty fish ≥3x/week)
- Depression driven by psychosocial factors without an inflammatory component
- People with bipolar depression (evidence is mixed and expert consultation is essential)
- Those expecting a rapid effect — omega-3 works slowly over weeks, not days
One practical approach before supplementing: ask your doctor to order an omega-3 index panel or simply a standard lipid panel that includes inflammatory markers. The results can calibrate whether omega-3 is likely to be high-yield for you specifically — exactly the kind of biomarker-level decision that personalized supplement platforms are built around. For context on why this biomarker-driven approach outperforms generic supplementation, personalized supplements vs. generic vitamins walks through the evidence on individualized vs. population-level protocols.
Age and sex also modulate response in ways the aggregate trial data can obscure. Older adults tend to have chronically lower omega-3 index scores and higher baseline inflammatory load, which may explain why several trials conducted in adults over 60 report larger effect sizes. Women in perimenopause and menopause face a related dynamic: estrogen decline amplifies neuroinflammatory tone, which EPA's resolvin-producing pathway directly counteracts. Omega-3's role in menopause symptoms explores how this hormonal-inflammatory overlap plays out in the evidence.
---
Omega-3 as an Adjunct, Not a Replacement
It is worth being direct: omega-3 should not replace antidepressant medication or psychotherapy in moderate-to-severe depression. The clinical evidence positions it as an adjunct — a meaningful one, but not a standalone treatment.
The exception is mild-to-moderate depressive symptoms in the context of clear omega-3 deficiency or high inflammatory load, where a therapeutic trial of EPA-dominant omega-3 before initiating pharmacotherapy is a reasonable, evidence-informed option to discuss with a physician.
One important safety note: if you are already prescribed an antidepressant, omega-3 is generally considered safe to add — multiple trials have used it as an augmentation strategy — but always inform your prescriber. At doses above 2 g EPA+DHA per day, mild antiplatelet effects may occur, which is relevant if you take blood-thinning medications or have a bleeding disorder.
---
What This Means for Your Formula
When Ones analyzes your health data — including blood work, dietary patterns, and symptoms — omega-3 status is one of the first nutritional factors flagged in the context of mood and inflammation. If your data supports it, Ones includes Omega-3 (EPA/DHA) dosed at clinical ranges, calibrated to your specific findings rather than a one-size-fits-all amount.
Beyond omega-3, two ingredients in the Ones catalog are particularly relevant to the neuroinflammatory and HPA-axis mechanisms behind depression:
- Ashwagandha (KSM-66, 600 mg): KSM-66 is the most clinically studied ashwagandha extract. A double-blind RCT (Chandrasekhar et al., Indian Journal of Psychological Medicine 2012; PMID: 23439798) found significant reductions in serum cortisol and perceived stress scores over 60 days. Chronic cortisol elevation is both a driver and a consequence of depression, making HPA-axis modulation a meaningful complement to EPA's anti-inflammatory pathway.
- Magnesium Complex: Magnesium deficiency is independently associated with higher rates of depression in epidemiological data, and magnesium plays a role in NMDA receptor regulation — a pathway targeted by newer antidepressant agents including esketamine. Ones uses a glycinate form for superior bioavailability and GI tolerance. A 2017 randomized clinical trial by Tarleton et al. (PLOS ONE; PMID: 28654669) found that 248 mg elemental magnesium daily over 6 weeks produced clinically significant improvements in PHQ-9 depression scores, with effects appearing within 2 weeks of starting supplementation.
Neither ingredient replaces EPA for the mood-specific mechanisms discussed above, which is why Ones builds formulas that address multiple pathways simultaneously rather than relying on any single nutrient. The formulas that emerge from a 6- or 9-capsule daily plan are built by the AI based on your actual data — not by selecting from a menu.
---
Key Takeaways
- EPA is the active fraction for depression, not DHA — formulas with ≥60% of omega-3 as EPA consistently outperform DHA-dominant or balanced products in clinical trials, with a network meta-analysis placing pure EPA at the top of the ranking (SMD −0.61).
- The effective dose is at least 1 g EPA/day, typically from 2–3 g total omega-3, taken with a fat-containing meal for optimal absorption; re-esterified triglyceride forms offer better bioavailability than ethyl ester forms without food.
- Effect size is meaningful but moderate — comparable to some second-line pharmacological agents in meta-analyses, strongest in people with deficiency or elevated inflammatory markers.
- Omega-3 works best as an adjunct, not a standalone treatment for moderate-to-severe depression; its role is clearest alongside existing antidepressant therapy or in early, mild presentations with documented deficiency.
- Inflammatory biomarkers and omega-3 index are the key stratifiers — knowing your baseline CRP and omega-3 status before supplementing removes the guesswork and predicts whether you are likely to be a high responder.
- Duration matters — expect 8–12 weeks of consistent dosing before judging effectiveness; the EPA ceiling effect seen in the Liao 2019 network meta-analysis suggests that more is not always better beyond the 1–2 g EPA/day range.
---
Always consult a qualified healthcare provider before starting or changing any supplementation protocol, especially alongside prescription antidepressant medications.